Immuno-oncology

CHDR aims to break new ground in early-stage clinical drug research. While our work spans a wide range of medical disciplines, early-phase immuno-oncology drug development is a special interest of ours. The rapidly changing field of immuno-oncology and the increasing complexity of trials in this area call for an expert approach.